SCHEMBL2376699

SCHEMBL2376699

[CH2]C(C)(C)Cc1cccnc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.51
CYP3A4 P08684 2/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
HIF1A Q16665 1/20 0.51
FDPS P14324 5/20 0.50
CHRNB2 P17787 3/20 0.50
CHRNA4 P43681 3/20 0.50
BTN3A1 O00481 1/20 0.50
PDE3A Q14432 1/20 0.50
CYP2D6 P10635 2/20 0.48
CHRNA7 P36544 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
SLC6A2 P23975 1/20 0.47
SLC6A4 P31645 1/20 0.47
SLC6A3 Q01959 1/20 0.47
KCNH2 Q12809 1/20 0.47
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31358573 0.83 CYP1A2 (0.55) CYP1A2CYP3A4CYP2C9CYP2C19HIF1A
SCHEMBL74145 0.83 CYP1A2 (0.55) CYP1A2CYP3A4CYP2C9CYP2C19HIF1A
Ammonia Solution, Strong SCHEMBL27962089 0.82 CHRNB2 (0.57) CYP1A2CYP3A4CYP2C9CYP2C19HIF1A
SCHEMBL2375127 0.80 FDPS (0.57) CYP1A2CYP3A4CYP2C9CYP2C19HIF1A
SCHEMBL7382527 0.80 FDPS (0.54) CYP1A2CYP3A4CYP2C9CYP2C19HIF1A
SCHEMBL15941315 0.80 SLC6A2 (0.57) CYP1A2CYP3A4CYP2C9CYP2C19HIF1A
SCHEMBL15516269 0.80 CYP1A2 (0.61) CYP1A2CYP3A4CYP2C9CYP2C19HIF1A
SCHEMBL19117642 0.80 CYP1A2 (0.51) CYP1A2CYP3A4CYP2C9CYP2C19HIF1A
SCHEMBL8366344 0.80 CHRNA7 (0.52) CYP1A2CYP3A4CYP2C9CYP2C19HIF1A
SCHEMBL13715387 0.78 L3MBTL1 (0.55) CYP1A2CYP3A4CYP2C9CYP2C19HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101180266-B As the alpha ketoamide compounds of cystatin Vero Bay (US) 2015-11-25 CN disclosed
CN-103787959-A N-2,2-dimethyl-3-arylpropylcaprylamide compound, its preparation method and its use in pharmacy UNIV CHINA PHARMA 2014-05-14 CN disclosed
US-8450373-B2 Alpha ketoamide compounds as cysteine protease inhibitors VIROBAY, INC. (US) 2013-05-28 US disclosed
EP-2511257-A2 Alpha ketoamide compounds as cysteine protease inhibitors ViroBay, Inc. (US) 2012-10-17 EP disclosed
US-20120190714-A1 ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS APPLERA CORPORATION (US) 2012-07-26 US disclosed
US-8013183-B2 Alpha ketoamide compounds as cysteine protease inhibitors VIROBAY, INC. (US) 2011-09-06 US disclosed
US-20100305331-A1 ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY, INC. (US) 2010-12-02 US disclosed
US-7696250-B2 Alpha ketoamide compounds as cysteine protease inhibitors VIROBAY, INC. (US) 2010-04-13 US disclosed
US-20100069244-A1 Pyridine Compounds for Combating Pests BASF SE (DE) 2010-03-18 US disclosed
CN-101568258-A Pyridine derivatives for combating pests BASF SE (DE) 2009-10-28 CN disclosed
US-20090170909-A1 ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY, INC. (US) 2009-07-02 US disclosed
US-7488848-B2 Alpha ketoamide compounds as cysteine protease inhibitors VIROBAY, INC. (US) 2009-02-10 US disclosed
CN-101180266-A Alpha ketoamide compounds as cysteine protease inhibitors APPLERA CORP (US) 2008-05-14 CN disclosed
EP-1865940-A2 ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS Applera Corporation (US) 2007-12-19 EP disclosed
US-20070021353-A1 Alpha ketoamide compounds as cysteine protease inhibitors APPLERA CORPORATION (US) 2007-01-25 US disclosed
WO-2006102243-A2 ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS APPLERA CORPORATION (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190714-A1 ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS CTSS, CTSF, CTSB CYP1A2 2477/4885CYP3A4 2066/4885CYP2C9 2124/4885
US-20090170909-A1 ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS CTSS, CTSF, CTSB CYP1A2 2477/4885CYP3A4 2066/4885CYP2C9 2124/4885
US-20070021353-A1 Alpha ketoamide compounds as cysteine protease inhibitors CTSS, CTSF, CTSB CYP1A2 2477/4885CYP3A4 2066/4885CYP2C9 2124/4885
US-20100305331-A1 ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS CTSS, CTSF, CTSB CYP1A2 2477/4885CYP3A4 2066/4885CYP2C9 2124/4885
US-20100069244-A1 Pyridine Compounds for Combating Pests CHRM1, PRDX1, CHRM2 CYP1A2 211/4885CYP3A4 918/4885CYP2C9 429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.